{
    "clinical_study": {
        "@rank": "31632", 
        "arm_group": {
            "arm_group_label": "Domperidone", 
            "arm_group_type": "Experimental", 
            "description": "Participants will received domperidone at a dose of 10mg given up to three times per day"
        }, 
        "brief_summary": {
            "textblock": "To provide oral domperidone to patients between the ages of 18 and 60 years of age,\n      according to the investigator's judgment, a prokinetic effect is needed for the relief of\n      severe gastroparesis. We have defined severe gastroparesis as 1) positive gastric emptying\n      scintigraphy (more than 10% residue at 4 hours), 2) nausea, 3) early satiety, 4) abdominal\n      pain. We will recruit patients for two years and the patients will be given domperidone for\n      up to two years."
        }, 
        "brief_title": "Domperidone for the Treatment of Chronic Nausea and Vomiting Secondary to Gastroparesis", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Actual"
        }, 
        "condition": "Patients With Gastroparesis Who Have Failed Standard Therapy.", 
        "condition_browse": {
            "mesh_term": [
                "Nausea", 
                "Vomiting", 
                "Gastroparesis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Male or Female\n\n          2. Age 18 - 60\n\n          3. Symptoms or manifestation secondary to gastroparesis such as vomiting, nausea, the\n             feeling you are full after you start eating, and abdominal pain.\n\n          4. Subjects must have a comprehensive evaluation to eliminate other causes of their\n             symptoms which includes gastric emptying scintigraphy, esophagogastroduodenoscopy\n             (EGD), and the patient's subjective symptoms.\n\n          5. Subject has signed informed consent for the administration of domperidone that\n             informs the patient of potential adverse events\n\n          6. Female subjects must be:\n\n               1. surgically sterile (have had a hysterectomy or bilateral oophorectomy, or tubal\n                  ligation)\n\n               2. if sexual active, practicing an effective method of birth control such as\n                  hormonal prescription oral contraceptives, progesterone implants or injections,\n                  contraceptive patch, intrauterine device, or maintenance of a monogamous\n                  relationship with a male partner who has been surgically sterilized by\n                  vasectomy. A double barrier method such as condoms, diaphragms, or cervical caps\n                  with spermicidal foam, cream, or gel may be used as a method of birth control\n\n        Exclusion Criteria:\n\n          1. History of, or current, arrhythmias including ventricular tachycardia, ventricular\n             fibrillation, atrial fibrilation and Torsade des Pointes, subjects with minor forms\n             of ectopy (PACs) are not necessarily excluded\n\n          2. Clinically significant bradycardia, sinus node dysfunction, or heart block. Prolonged\n             QTc (QTC>450 milliseconds for males, QTc>470 milliseconds for females)\n\n          3. Clinically significant electrolyte disorders\n\n          4. Gastrointestinal hemmorrhage or obstruction\n\n          5. Presence of a prolactinoma (prolactin-releasing pituitary tumor)\n\n          6. Pregnant or breast feeding female\n\n          7. Known allergy to domperidone The following medications are prohibited during the\n             study: antidepressants: doxepin, clomipramine, amopxapine, trazodone, venlafaxine,\n             nefazodone, fluvoxamine, paroxetine, fluoxetine, sertraline, amitriptyline,\n             maprotiline, desipramine, nortriptyline, trimipramine, imipramine, protriptyline;\n             anti-psychotics: haloperidol, chlorpromazine, chlorpromazine pimozide, sertindole,\n             quetiapine, mesoridazine, perphenazine, lfluphenazine, promazine, trifluoperazine;\n             anti-emetics: prochlorperazine, thioridazine, promethazine, mesoridazine,\n             theiethylperazine, perphazine, dolasetron, dronabinol, droperidol; anti-infective\n             agents: erythromycin, clarithromycin, troleandomycin, norfloxcin, quinine sulfate,\n             quinupristin and dalfopristin, pentamidine, sparfloxacin, grepafloxacin,\n             azithromycin, ofloxacin, levofloxacin; anti-fungal agents: fluconazole, itraconazole,\n             ketoconazole, miconazole, terconazole, ticonazole, butaconazole; antivirals:\n             foscarnet; protease inhibitors: indinavir, amprenavir, ritonavir, nelfinavir,\n             squinavir; antihypertensives: nicardipine, isradipine, moexipril/HCTZ; calcium\n             channel blockers: verapamil, diltiazem, deltiazem/enalapril, verapamil/trandolapril,\n             tocainide, bepridil; anti-arrhythmics: disopyramide, quinidine, procainamide,\n             flecainide, sotalol, bretylium, amiodarone, ibutilide, moricizine; diueretics:\n             bumetanide, furosemide, torsemide, etharcrynic acid, chlorothiazide, indapamide;\n             antilipemics: probucol, bepridil, mibefradil; hematological agents: cilostazol;\n             respiratory agents: zafirlukast, salmetrol; gastrointestinal agents: cimetidine,\n             cisapride; antidiarrheal: octreotide; antihistamines: azelastine, clemastine;\n             migraine treatment: naratriptan, sumatriptan, zolmitriptan; antimalarial:\n             halofantrine; muscle relaxants: tizanidine; narcotic dependence: levomethadyl;\n             miscellaneous: tamoxifen, warfarin, phenytoin, ziprasidone, risperidone, formoterol\n             fumarate, sildenafil; drugs that prolong the QT Interval: albuterol, alfuzosin,\n             amantadine, amisulpride, amphetamine, arsenic trioxide, astemizole, atazanavir,\n             atomoxetine, chloral hydrate, chloroquine, ciprofloxacin, citalopram, clozapine,\n             cocaine, dexmethylphenidate, diphenhydramine, dobutamine, dofetilide, dopamine,\n             dronedarone, ephedrine, epinephrine, eribulin, escitalopram, famotidine, felbamate,\n             fenfluramine, fingolimod, fosphenytoin, galantamine, gatifloxacin, gemifloxacin,\n             granisetron, iloperidone, isoproterenol, lapatinib, levalbuterol, lisdexamfetamine,\n             lithium, metaproterenol, methadone, methylphenidate, midodrine, moxifloxacin,\n             nilotinib, norepinephrine, ondansetron, oxytocin, paliperidone, perflutren lipid\n             microspheres, phentermine, phenylephrine, phenylpropanolamine, protriptyline,\n             pseudoephedrine, ranolazine, ritodrine, toxithromycin, sibutramine, solifenacin,\n             sunitinib, tacrolimus, telithromycin, terbutaline, terfenadine, tolterodine,\n             trimethoprim-sulfa, vandetanib, vardenafil, voriconazole."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 18, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01711918", 
            "org_study_id": "Domperidone"
        }, 
        "intervention": {
            "arm_group_label": "Domperidone", 
            "description": "oral tablet; dose is 10mg per tablet given up to 3 times daily.", 
            "intervention_name": "Domperidone", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Domperidone"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "gastroparesis", 
            "domperidone", 
            "nausea", 
            "vomiting"
        ], 
        "lastchanged_date": "April 24, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Iowa City", 
                    "country": "United States", 
                    "state": "Iowa", 
                    "zip": "52242"
                }, 
                "name": "University of Iowa Hospitals and Clinics"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Domperidone for the Treatment of Chronic Nausea and Vomiting Secondary to Gastroparesis", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "A subject will be considered a responder, if they report on a 6 point Likert scale that when compared to baseline, their symptoms are either 'somewhat better or markedly better'.", 
            "measure": "Improvement of overall symptoms based on likert scale", 
            "safety_issue": "No", 
            "time_frame": "Baseline and End of study (2 years or last visit if patient withdraws)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01711918"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Iowa", 
            "investigator_full_name": "Ron Schey", 
            "investigator_title": "Clinical Assistant Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "A subject will be considered a responder, if they report on a 6 point Likert scale that when compared to baseline, their symptoms are either 'somewhat better or markedly better'.", 
                "measure": "Improvement of nausea based on likert scale", 
                "safety_issue": "No", 
                "time_frame": "Baseline and End of study (2 years or last visit if patient withdraws)"
            }, 
            {
                "description": "A subject will be considered a responder, if they report on a 6 point Likert scale that when compared to baseline, their symptoms are either 'somewhat better or markedly better'.", 
                "measure": "Improvement of vomiting based on likert scale", 
                "safety_issue": "No", 
                "time_frame": "Baseline and End of study (2 years or last visit if patient withdraws)"
            }, 
            {
                "description": "A subject will be considered a responder, if they report on a 6 point Likert scale that when compared to baseline, their symptoms are either 'somewhat better or markedly better'.", 
                "measure": "Improvement of abdominal bloating or distention based on likert scale", 
                "safety_issue": "No", 
                "time_frame": "Baseline and End of study (2 years or last visit if patient withdraws)"
            }, 
            {
                "description": "A subject will be considered a responder, if they report on a 6 point Likert scale that when compared to baseline, their symptoms are either 'somewhat better or markedly better'.", 
                "measure": "Improvement of premature abdominal fullness after meals based on likert scale", 
                "safety_issue": "No", 
                "time_frame": "Baseline and End of study (2 years or last visit if patient withdraws)"
            }
        ], 
        "source": "University of Iowa", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Iowa", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}